Abhinaya Rao
Internal Medicine · Sparks, NVNPI 1831622059
Payments from drug & device makers
Across 109 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$587
- GSK$239
- Novo Nordisk$186
- AbbVie$126
- Pfizer$118
- Lilly USA, LLC$115
- plus $697 from 23 others
What the payments were for
- Food & beverage$1,82688%
- Education$24212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 18 | $587 |
| GSK | 16 | $239 |
| Novo Nordisk | 12 | $186 |
| AbbVie | 8 | $126 |
| Pfizer | 6 | $118 |
| Lilly USA, LLC | 7 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Abbott | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Bayer | 2 | $36 |
| Merck | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 1 | $32 |
| AstraZeneca | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Vertex | 1 | $27 |
| CMP Pharma, Inc. | 1 | $25 |
| Nevro Corp. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
How this compares
$2,068 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 63 | $130,900 |
| OzempicSemaglutide | 44 | $80,192 |
| EliquisApixaban | 58 | $55,315 |
| JanuviaSitagliptin Phosphate | 42 | $53,346 |
| JardianceEmpagliflozin | 30 | $52,048 |
| RybelsusSemaglutide | 31 | $42,501 |
| TrulicityDulaglutide | 16 | $35,832 |
| XareltoRivaroxaban | 27 | $31,085 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $17,115 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,118 |
| Atorvastatin Calcium | 784 | $10,165 |
| FarxigaDapagliflozin Propanediol | 13 | $8,355 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $7,580 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $115 | $166,73379 claims |
| Novo NordiskOzempic, Rybelsus | $186 | $122,69375 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $43 | $64,35053 claims |
| MerckJanuvia, Janumet Xr | $35 | $57,16856 claims |
| PfizerEliquis | $118 | $55,31558 claims |
| GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $239 | $51,137108 claims |
| Johnson & JohnsonXarelto | $15 | $31,08527 claims |
| AstraZenecaFarxiga, Symbicort | $28 | $11,52727 claims |
| AbbVieSynthroid | $126 | $2,92234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Sparks
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Marigene Salazar SharmaHenderson$2.5M
- Mavis MatsumotoHenderson$1.8M
- Vrijendra HoonLas Vegas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.